BillionToOne stock
Private-market facts for current and former BillionToOne employees researching their stock.
Overview
BillionToOne develops molecular diagnostics, including its UNITY prenatal test that uses a single blood draw from the mother to screen for genetic conditions without needing a sample from the father.
BillionToOne outlook
For employees evaluating BillionToOne equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices. The upside scenario at 2x is relatively close to the base case, suggesting more predictable but narrower range of outcomes.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling BillionToOne shares
Why shareholders consider selling
Shareholders in BillionToOne may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, BillionToOne does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell BillionToOne stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing BillionToOne shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of BillionToOne shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series D round and its reported $1B valuation can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for BillionToOne shareholders
Exploring equity in BillionToOne often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
BillionToOne most recently raised a Series D round in June 2024. The company was valued at $1B. Total funding raised to date is approximately $400M.
Lead investors in this round include Adams Street Partners and Hummingbird Ventures.
Founders & company background
BillionToOne was founded in 2016 by Oguzhan Atay and is headquartered in Menlo Park, CA.
Investors
Industry
Similar private companies
Latest BillionToOne news
Frequently asked questions
- Is BillionToOne still a private company?
- Yes, BillionToOne is currently a private company.
- What is BillionToOne's latest funding round?
- BillionToOne's most recent known round is Series D, raised in June 2024.
- What is BillionToOne's valuation?
- BillionToOne's latest reported valuation is $1B.
- Who are the investors in BillionToOne?
- Notable investors include Adams Street Partners, Hummingbird Ventures.
- Can I sell my BillionToOne stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands BillionToOne stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · BillionToOne data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.